ERBB2 and breast cancer: Our study highlighted that pretreatment high NLR (≥ 2.53) was a prognostic biomarker associated with worse PFS and OS in women treated with first-line CdK4/6i and ET for metastatic or locally advanced HR+/HER2- breast cancer.